Status:
COMPLETED
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
Lead Sponsor:
University Hospital, Ghent
Conditions:
COVID-19
Deep Vein Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
To see whether our increased dosing regimen of unfractionated heparin (UF) and low molecular weight heparin (LMWH) in COVID-19 patients was effective at preventing thrombo-embolic complications. We di...
Detailed Description
COVID-19 took the world by storm with its fast spread, high number of infected patients and its potential to range from mild illness to very severe respiratory distress. This pandemic is currently the...
Eligibility Criteria
Inclusion
- 18 years or older
- Hospitalisation required
- ICU admission
Exclusion
- Coagulopathies prior to COVID 19 infection (known thromboembolism in the last 6 months i.e. deep venous thrombosis, pulmonary embolism, …)
- Therapeutic anticoagulation on moment of ICU admission
- Major trauma
- Major bleeding
- Cerebro vascular accident or neuro trauma in the last month
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2022
Estimated Enrollment :
813 Patients enrolled
Trial Details
Trial ID
NCT05224388
Start Date
January 1 2020
End Date
September 15 2022
Last Update
May 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghent University Hospital
Ghent, Belgium, 9000